Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Running, not enrolling · Phase 2

Conditions studied: Salivary Cancer

In brief

This study will test any good and bad effects of the study drug called enzalutamide. Enzalutamide could shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least 30% compared to its present size, in at least 1 out of 5 patients. Enzalutamide is not FDA approved to treat salivary gland cancer, but it has already been FDA-approved to treat other cancers.

Key facts

Study ID
NCT02749903
Run by
Alliance for Clinical Trials in Oncology
People needed
46
Starts
2016-09-14
Expected to finish
2028-07-05
Last updated by the study team
2026-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.